In early‐stage HER2+ breast cancer, neither the average level of HER2 protein expression nor the average level of HER2 gene amplification across a tumor seem to have an impact on therapy response (Wolff et al., 2013; Zabaglo et al., 2013). The gene discussed is ERBB2; the disease is breast carcinoma.